Dupilumab treatment in COPD patients with type 2 inflammation resulted in significant reductions in key inflammatory biomarkers (total IgE, FeNO, eotaxin-3, PARC) versus placebo.
Greater reductions in exacerbation risk were observed in patients with higher baseline blood eosinophil counts and FeNO levels.
These findings support biomarker-guided selection of biologic therapy in COPD, particularly for patients with evidence of type 2 inflammation.
